This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-betal, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, in particular for the treatment of cancer, metastases, disease of the nervous system or immunosuppression, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-betal, TGF-beta3, VEGF, interleukin- 10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about I microM to about 25 microM. - 7/7 Figure 5 0 - Figure 6 1,00 0,75 0,50 ---- ,e 0ee censored values 0,25 - control "'"'"I .. 80 microM - 10 microM 0,0 100 200 300 400 500 600 700 800
